MX2019012088A - Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias. - Google Patents

Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.

Info

Publication number
MX2019012088A
MX2019012088A MX2019012088A MX2019012088A MX2019012088A MX 2019012088 A MX2019012088 A MX 2019012088A MX 2019012088 A MX2019012088 A MX 2019012088A MX 2019012088 A MX2019012088 A MX 2019012088A MX 2019012088 A MX2019012088 A MX 2019012088A
Authority
MX
Mexico
Prior art keywords
antagonist combination
propylamino
benzothiazole
tetrahydro
amine
Prior art date
Application number
MX2019012088A
Other languages
English (en)
Inventor
N Chase Thomas
E Clarence-Smith Kathleen
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MX2019012088A publication Critical patent/MX2019012088A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención describe el uso de un antagonista de NK1, en combinación con 6-propilamino-A,5,6,7-tetrahidro-1,3-benzotiazo l-2-amina, para facilitar el tratamiento de un paciente que padezca una sinucleinopatía al permitir que una dosis diaria terapéuticamente efectiva de 6-propilam¡no-A,5,6,7-tetrahidro-1,3- benzotiazoI-2-amina actúe sin los efectos adversos típicos causados por el diclorhidrato de pramipexol monohidratado cuando se administra solo.
MX2019012088A 2017-04-10 2018-04-09 Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias. MX2019012088A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483555P 2017-04-10 2017-04-10
PCT/US2018/026699 WO2018191160A1 (en) 2017-04-10 2018-04-09 Nk1-antagonist combination and method for treating synucleinopathies

Publications (1)

Publication Number Publication Date
MX2019012088A true MX2019012088A (es) 2020-02-07

Family

ID=63792736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012088A MX2019012088A (es) 2017-04-10 2018-04-09 Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.

Country Status (14)

Country Link
US (1) US11160809B2 (es)
EP (1) EP3609495A4 (es)
JP (1) JP7271437B2 (es)
KR (1) KR20200002899A (es)
CN (1) CN110730662A (es)
AU (1) AU2018251604B2 (es)
BR (1) BR112019021125A2 (es)
CA (1) CA3059418A1 (es)
EA (1) EA201992414A1 (es)
IL (2) IL269875B1 (es)
MA (1) MA51658A (es)
MX (1) MX2019012088A (es)
TW (1) TWI803488B (es)
WO (1) WO2018191160A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645120A4 (en) * 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
KR100214905B1 (ko) 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
ATE282417T1 (de) * 1996-12-02 2004-12-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
KR100501608B1 (ko) 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
ES2272408T3 (es) 2000-12-14 2007-05-01 F. Hoffmann-La Roche Ag Matriz lipidica autoemulsificante (selm).
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
CA2554346C (en) 2004-01-30 2009-11-17 Pfizer Products Inc. Parenteral formulations comprising a beta-cyclodextrin and a preservative
US20120253047A1 (en) 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
ES2350647T3 (es) * 2005-03-08 2011-01-25 Janssen Pharmaceutica Nv Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1).
AU2006269383A1 (en) 2005-07-11 2007-01-18 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
DE602006009670D1 (de) 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl) 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
CN101641096A (zh) * 2006-12-14 2010-02-03 诺普神经科学股份有限公司 (r)-普拉克索的组合物以及使用该组合物的方法
CN101677564A (zh) 2007-03-14 2010-03-24 诺普神经科学股份有限公司 (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法
US20080254117A1 (en) 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2012140604A1 (en) 2011-04-15 2012-10-18 Sandoz Ag Stable formulations of pramipexole hydrochloride
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
JP2016532660A (ja) 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
EP3193830B1 (en) 2014-09-19 2023-11-01 Heron Therapeutics, Inc. Emulson formulations of aprepitant
US9850267B2 (en) 2015-06-03 2017-12-26 Navinta, Llc Crystalline fosaprepitant dicyclohexylamine salt and its preparation
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION

Also Published As

Publication number Publication date
IL269875B1 (en) 2024-02-01
CN110730662A (zh) 2020-01-24
WO2018191160A1 (en) 2018-10-18
AU2018251604A1 (en) 2019-11-21
EA201992414A1 (ru) 2020-03-16
BR112019021125A2 (pt) 2020-05-12
EP3609495A4 (en) 2020-12-02
TWI803488B (zh) 2023-06-01
AU2018251604B2 (en) 2022-04-14
JP2020516625A (ja) 2020-06-11
TW201841634A (zh) 2018-12-01
EP3609495A1 (en) 2020-02-19
JP7271437B2 (ja) 2023-05-11
US11160809B2 (en) 2021-11-02
CA3059418A1 (en) 2018-10-18
MA51658A (fr) 2020-12-02
US20200147097A1 (en) 2020-05-14
IL309770A (en) 2024-02-01
IL269875A (es) 2019-12-31
KR20200002899A (ko) 2020-01-08

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2017006454A (es) Administracion sublingual de riluzol.
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2017006446A (es) Administracion sublingual de riluzol.
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
AU2018205275B2 (en) Methods for the treatment of neurological disorders
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021002322A (es) Nuevos metodos.
MX2020009942A (es) Compuestos y usos de los mismos.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2019012088A (es) Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
EA202193276A1 (ru) Способы лечения холангиокарциномы
PH12020551527A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
MX2021015390A (es) Tratamiento para sinucleinopatias.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.